Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 456.44 USD -1.91% Market Closed
Market Cap: 60.3B USD

Intrinsic Value

The intrinsic value of one ALNY stock under the Base Case scenario is hidden USD. Compared to the current market price of 456.44 USD, Alnylam Pharmaceuticals Inc is hidden .

The Intrinsic Value is calculated as the average of DCF and Relative values:

ALNY Intrinsic Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation History
Alnylam Pharmaceuticals Inc

Intrinsic Value History
Dive into the past to invest in the future

ALNY looks overvalued. Yet it might still be cheap by its own standards. Some stocks live permanently above intrinsic value; Historical Valuation reveals whether ALNY usually does or if today's premium is unusual.

Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Show Historical Valuation
What is Valuation History?
Ask AI Assistant
What other research platforms think about ALNY?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is ALNY valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Alnylam Pharmaceuticals Inc.

Explain Valuation
Compare ALNY to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Despite Alnylam’s leadership in RNAi therapies, the company’s path to consistent profitability is not guaranteed, given its reliance on a relatively small number of approved drugs and uncertainty around insurance coverage, which could constrain revenue growth.

Bull Theses

Alnylam’s first-to-market advantage in RNAi therapeutics positions it to capture significant market share in rare disease segments. Strong demand for its commercialized products, such as ONPATTRO and GIVLAARI, could drive robust revenue growth.

Show More Less
How do you feel about ALNY?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Alnylam Pharmaceuticals Inc

Current Assets 3.6B
Cash & Short-Term Investments 2.9B
Receivables 567.1m
Other Current Assets 219m
Non-Current Assets 922.3m
PP&E 692.2m
Other Non-Current Assets 230.1m
Current Liabilities 1.3B
Accounts Payable 102.4m
Accrued Liabilities 965.1m
Other Current Liabilities 233.4m
Non-Current Liabilities 3B
Long-Term Debt 1B
Other Non-Current Liabilities 2B
Efficiency

Free Cash Flow Analysis
Alnylam Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Alnylam Pharmaceuticals Inc

Revenue
2.5B USD
Cost of Revenue
-402.7m USD
Gross Profit
2.1B USD
Operating Expenses
-2.2B USD
Operating Income
-180.2m USD
Other Expenses
-138.9m USD
Net Income
-319.1m USD
Fundamental Scores

ALNY Profitability Score
Profitability Due Diligence

Alnylam Pharmaceuticals Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Positive 3Y Average ROE
ROE is Increasing
Exceptional Gross Margin
hidden
Profitability
Score

Alnylam Pharmaceuticals Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.

ALNY Solvency Score
Solvency Due Diligence

Alnylam Pharmaceuticals Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Negative Net Debt
Short-Term Solvency
Long-Term Solvency
hidden
Solvency
Score

Alnylam Pharmaceuticals Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALNY Price Targets Summary
Alnylam Pharmaceuticals Inc

Wall Street analysts forecast ALNY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALNY is 492.12 USD with a low forecast of 238.36 USD and a high forecast of 609 USD.

Lowest
Price Target
238.36 USD
48% Downside
Average
Price Target
492.12 USD
8% Upside
Highest
Price Target
609 USD
33% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Alnylam Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ALNY is hidden .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
HIDDEN
Show
Dividend Yield
No dividends
Buyback Yield
HIDDEN
Debt Paydown Yield
HIDDEN

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ALNY Insider Trading
Buy and sell transactions by insiders

ALNY News

Other Videos
What is the Intrinsic Value of one ALNY stock?

The intrinsic value of one ALNY stock under the Base Case scenario is hidden USD.

Is ALNY stock undervalued or overvalued?

Compared to the current market price of 456.44 USD, Alnylam Pharmaceuticals Inc is hidden .

Back to Top